Pharmacoeconomic review report: Ertugliflozin (Steglatro) (Merck Canada Inc.) indication : type 2 diabetes mellitus
Ertugliflozin is an oral antidiabetic drug belonging to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. It is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM) for whom metformin is inappropriate due to contrai...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
February 2019, 2019
|
| Edition: | Final |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references